Literature DB >> 6301492

Desensitization of corticotropin-releasing factor receptors.

T Reisine, A Hoffman.   

Abstract

Pretreatment of rat anterior pituitary cells with corticotropin releasing factor (CRF) rapidly and markedly reduced the ability of CRF to restimulate cyclic AMP formation and adrenocorticotropic hormone (ACTH) release. The effect was dependent on the length of time of pretreatment as well as the concentration of CRF. Neither basal nor intracellular immunoreactive ACTH levels nor basal cyclic AMP content were affected. CRF's stimulatory action on cyclic AMP formation and ACTH release recovered within one hour following CRF pretreatment. Forskolin, a compound that directly activates adenylate cyclase also releases ACTH from these cells. Pretreatment with CRF did not alter forskolin-stimulated cyclic AMP accumulation or ACTH secretion. Furthermore, CRF pretreatment did not change epinephrine's ability to increase the release of ACTH. These results indicate that CRF can regulate the responsiveness of its own receptor.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6301492     DOI: 10.1016/0006-291x(83)91387-6

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  10 in total

1.  Expression cloning of a human corticotropin-releasing-factor receptor.

Authors:  R Chen; K A Lewis; M H Perrin; W W Vale
Journal:  Proc Natl Acad Sci U S A       Date:  1993-10-01       Impact factor: 11.205

Review 2.  Corticotropin releasing factor (CRF) receptor signaling in the central nervous system: new molecular targets.

Authors:  Richard L Hauger; Victoria Risbrough; Olaf Brauns; Frank M Dautzenberg
Journal:  CNS Neurol Disord Drug Targets       Date:  2006-08       Impact factor: 4.388

Review 3.  Psychiatric implications of altered limbic-hypothalamic-pituitary-adrenocortical activity.

Authors:  F Holsboer
Journal:  Eur Arch Psychiatry Neurol Sci       Date:  1989

4.  Lithium induces corticotropin secretion and desensitization in cultured anterior pituitary cells.

Authors:  M Zatz; T D Reisine
Journal:  Proc Natl Acad Sci U S A       Date:  1985-02       Impact factor: 11.205

5.  Two distinct corticotrophin releasing activities of vasopressin.

Authors:  J C Buckingham
Journal:  Br J Pharmacol       Date:  1985-01       Impact factor: 8.739

6.  Role of cholecystokinin in corticotropin release: coexistence with vasopressin and corticotropin-releasing factor in cells of the rat hypothalamic paraventricular nucleus.

Authors:  E Mezey; T D Reisine; L Skirboll; M Beinfeld; J Z Kiss
Journal:  Proc Natl Acad Sci U S A       Date:  1986-05       Impact factor: 11.205

7.  Basolateral amygdala corticotropin-releasing factor receptor type 1 regulates context-cocaine memory strength during reconsolidation in a sex-dependent manner.

Authors:  Jobe L Ritchie; Jennifer L Walters; Justine M C Galliou; Robert J Christian; Shuyi Qi; Marina I Savenkova; Christopher K Ibarra; Shayna R Grogan; Rita A Fuchs
Journal:  Neuropharmacology       Date:  2021-10-02       Impact factor: 5.250

Review 8.  Physiological and neurochemical aspects of corticotropin-releasing factor actions in the brain: the role of the locus coeruleus.

Authors:  H Lehnert; C Schulz; K Dieterich
Journal:  Neurochem Res       Date:  1998-08       Impact factor: 3.996

Review 9.  Using high resolution imaging to determine trafficking of corticotropin-releasing factor receptors in noradrenergic neurons of the rat locus coeruleus.

Authors:  B A S Reyes; D A Bangasser; R J Valentino; E J Van Bockstaele
Journal:  Life Sci       Date:  2014-07-21       Impact factor: 5.037

10.  Carboxyl-terminal and intracellular loop sites for CRF1 receptor phosphorylation and beta-arrestin-2 recruitment: a mechanism regulating stress and anxiety responses.

Authors:  Robert H Oakley; J Alberto Olivares-Reyes; Christine C Hudson; Fabiola Flores-Vega; Frank M Dautzenberg; Richard L Hauger
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2007-03-15       Impact factor: 3.619

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.